Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...
Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...
was filed for approval in the US as an add-on therapy for major depressive disorder (MDD), part of a plan to build sales of the drug to a peak of $4 billion or more. Vraylar, sold in some markets ...
The treatment effect was mixed however, as has been seen in other trials of the drug in this setting. There was a significant effect at the lower 1.5mg/day dose of Vraylar, with 44% of patients ...